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Invariant natural killer T (iNKT) cells are evolutionarily
conserved innate T cells that influence inflammatory
responses. We have shown that iNKT cells, previ-
ously thought to be rare in humans, were highly en-
riched in human and murine adipose tissue, and
that as adipose tissue expanded in obesity, iNKT
cells were depleted, correlating with proinflamma-
tory macrophage infiltration. iNKT cell numbers
were restored in mice and humans after weight
loss. Mice lacking iNKT cells had enhanced weight
gain, larger adipocytes, fatty livers, and insulin resis-
tance on a high-fat diet. Adoptive transfer of iNKT
cells into obese mice or in vivo activation of iNKT
cells via their lipid ligand, alpha-galactocylceramide,
decreased body fat, triglyceride levels, leptin, and
fatty liver and improved insulin sensitivity through
anti-inflammatory cytokine production by adipose-
derived iNKT cells. This finding highlights the poten-
tial of iNKT cell-targeted therapies, previously proven
to be safe in humans, in the management of obesity
and its consequences.
INTRODUCTION
The discovery that tumor necrosis factor alpha (TNF-a) was
elevated in obesity and correlated with insulin resistance was
a seminal finding that kick-started the field of inflammation and
immunometabolism in 1993 (Hotamisligil et al., 1993). It is now
accepted that inflammation, particularly within adipose tissue it-
self (Hotamisligil, 2006; Hotamisligil et al., 1993; Nishimura et al.,
2008; Shoelson et al., 2006), is critically linked to obesity and its
accompanying metabolic disorders, including impaired glucose
tolerance, insulin resistance, hepatic steatosis, dyslipidemia,
and eventually type 2 diabetes (Reaven, 1988). Adipose tissue
is immunologically dynamic, containing resident CD4+ (Winer
et al., 2009) and CD8+ T cells (Nishimura et al., 2009), regulatory574 Immunity 37, 574–587, September 21, 2012 ª2012 Elsevier Inc.T (Treg) cells (Feuerer et al., 2009), B cells (Winer et al., 2011),
and macrophages (Lumeng et al., 2007; Weisberg et al., 2003;
Wentworth et al., 2010), each of which have been shown to
play positive or negative roles in metabolic dysregulation and
the development of obesity (Feuerer et al., 2009; Lumeng
et al., 2007; Nishimura et al., 2009; Wentworth et al., 2010; Winer
et al., 2011; Winer et al., 2009).
Chronic low-grade inflammation in obese fat may activate
resident innate immune cells, leading to inappropriate immune
responses and the development of insulin resistance (Xu et al.,
2003). Likewise, inflammation associated with adiposity is partly
generated by fat-resident immune cells, the most widely studied
being macrophages, which infiltrate fat during obesity and
undergo phenotypic switching, leading to the development of
insulin resistance (Lumeng et al., 2007; Weisberg et al., 2003).
Macrophage activation is modified by T cells. Interferon-g
(IFN-g) production by T cells enhances proinflammatory M1
macrophage differentiation, whereas T cells secreting anti-
inflammatory cytokines such as interleukin-4 (IL-4), IL-13, and
IL-10 promote anti-inflammatory M2 macrophage development
(Tiemessen et al., 2007; Kim et al., 2008). Classical CD11c-ex-
pressing M1 macrophages (Fujisaka et al., 2009; Lumeng
et al., 2007) often aggregate around necrotic adipocytes and
produce excess proinflammatory cytokines, such as IL-6 and
TNF-a, characteristic of obese adipose tissue in humans (Went-
worth et al., 2010) and mice (Lumeng et al., 2007). Alternatively
activated M2 macrophages (F4/80+CD11cCD206+) found in
lean adipose tissue generate high amounts of anti-inflammatory
cytokines, such as IL-10, but are decreased in obesity (Fujisaka
et al., 2009; Lumeng et al., 2007). Although the importance of
macrophages and their interaction with adipocytes and other
immune cells is now accepted as key in the development of
adipocyte and metabolic dysfunction, the mechanisms regu-
lating these interactions are not well understood.
We have explored a role for the innate T lymphocyte popula-
tion of invariant natural killer T (iNKT) cells in obesity and have
previously shown that iNKT cells are enriched in human adipose
tissue but are decreased in human obesity (Lynch et al., 2009).
iNKT cells constitute a unique innate T cell population, which is
highly conserved and expresses invariant T cell receptors
(TCRs) Va24Ja18, paired with Vb11 in humans, and Va14Ja18,
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TCRs recognize glycolipid ligands presented by the major histo-
compatibility complex-like molecule CD1d (Brigl and Brenner,
2004; Gumperz, 2006; Matsuda et al., 2000). The most studied
lipid antigen is alpha-galactosylceramide (aGC) (Matsuda
et al., 2000), as physiological lipid ligand(s) have yet to be fully
defined (Fox et al., 2009; Speak et al., 2007). A striking feature
of iNKT cells is their rapid production of both T helper 1 (Th1)
and Th2 cell cytokines upon activation with aGC (Bendelac
et al., 2007; Berzins et al., 2011; Matsuda et al., 2008), probably
accounting for their immunoregulatory potential. Indeed, iNKT
cell cytotoxicity and rapid production of IFN-g have been shown
to protect against tumor development, and iNKT cells also play
immunoregulatory roles in type 1 diabetes, multiple sclerosis,
and rheumatoid arthritis (Berzins et al., 2011; Swann et al.,
2007; Wu and Van Kaer, 2009). Our previous study reported
that iNKT cells are enriched in human fat at higher numbers
than elsewhere in the body (Lynch et al., 2009). Here, we have
shown that, like that of humans, murine adipose tissue was en-
riched with iNKT cells. Under physiological conditions of clonal
abundance, the number of iNKT cells probably exceeds a given
number of antigen-specific T cells by up to 10,000-fold, and thus
it is probable that iNKT cells will play an important immune regu-
latory role in adipose tissue. Furthermore, we showed that iNKT
cells resident in fat represent a unique subset with distinct Th2
cell cytokine production compared to iNKT cells in the liver
and spleen. Given the potent influence of other fat-resident
immune cells on the development of obesity and metabolic
outcomes, the conservation of iNKT cells in fat in mammals,
and the unique anti-inflammatory profile of fat-resident iNKT
cells, we hypothesized that local fat-resident iNKT cell popula-
tions would play a physiological role in adipose tissue regulation.
Our data confirm this hypothesis and show that iNKT cells confer
protection against the development of metabolic syndrome and
inflammation following a high fat diet (HFD) challenge.
RESULTS
iNKT Cells Are Depleted in Fat and Liver during the
Development of Obesity
We have previously shown that iNKT cells are enriched in human
fat but are depleted in obesity (Lynch et al., 2009). As it was not
possible to obtain adipose tissue from patients at multiple time
points after bariatric surgery, we looked in human peripheral
blood and found that iNKT cells were also reduced in the circu-
lation of obese patients compared to lean, healthy, age-matched
controls (Figure 1A). Cross-sectional analysis found that circu-
lating iNKT cell numbers were increased in obese patients who
had lost weight after Roux-en-Y gastric bypass (RYGB) surgery
compared to obese patients pre-RYGB surgery, although iNKT
cells were still reduced compared to lean controls (Figure 1A).
We then followed a group of patients (n = 7) longitudinally pre-
and post-RYGB surgery whose body mass index (BMI)
decreased from grade III obesity (mean BMI >50 kg/m2) to grade
II obesity (mean BMI 35–40 kg/m2) 18 months postsurgery (Fig-
ure 1A). Peripheral iNKT cell numbers increased in each patient
after weight loss (Figure 1A).
To further explore the relationship between obesity and iNKT
cells, we turned to murine models. We first determined whetherImiNKT cells were also present in murine fat. As in humans, iNKT
cells are enriched in murine adipose tissue (Figure 1B) at
numbers equivalent to those found in murine liver. Fat-derived
iNKT cells produced significantly less IFN-g and more IL-4 and
IL-10 compared to iNKT cells from the liver and spleen following
aGCactivation in vivo (Figure 1C) and in vitro (Figure 1D).We also
compared other lymphoid populations from adipose tissue to
those from liver and spleen. Similar to liver, fat had high levels
of NK and NKR+ T cells and high numbers of CD4CD8 double
negative (DN) T cells, reflecting the increased numbers of DN
iNKT cells in liver and fat (Figure S1A available online). Further-
more, of the iNKT cells, there were fewer CD4+ iNKT and more
DN iNKT cells in fat compared to those in the liver and spleen
(Figure S1B). Adipose tissue contained a small but significant
population of Treg (FoxP3+CD25+CD4+) cells (6%), similar to
those in the spleen (7%of T cells) and in agreementwith numbers
previously reported (Feuerer et al., 2009) (Figures S1A and S1C).
iNKT cells were previously shown to express FoxP3 in certain
circumstances (Monteiro et al., 2010). Given the high levels of
iNKT cells and the substantial population of Treg cells in fat, it
was necessary to determine whether there was any overlap
between both populations. Figure S1C shows that iNKT cells
are distinct from FoxP3+ Treg cells. Thus, the immune repertoire
in fat is unique, but with similarities both to liver in NK, NKR+T,
and iNKT levels and to spleen in Treg cell levels.
We next investigated the effects of obesity on iNKT cells using
two murine models of obesity: diet-induced obesity (DIO) and
obesity due to leptin deficiency (ob/ob). Mice fed a HFD for
6 weeks hadmarkedly reduced numbers of iNKT cells in adipose
tissue and liver (Figures 1E and 1F). iNKT cell depletion was even
more pronounced in ob/ob mice (Figure 1F), which were heavier
and had higher fasting blood glucose than DIO mice. We next
analyzed iNKT cell numbers during the development of obesity.
iNKT numbers in fat were reduced at as early as week 2 of the
HFD and steadily declined each week during the course of
the HFD (Figure 1G). iNKT levels also declined in the liver upon
HFD challenge, with significant differences seen from week 6
onward. Splenic iNKT cell levels fluctuated, with a trend toward
depletion at week 10 (Figure 1G). We also calculated absolute
numbers of iNKT cells per organ and per gram of fat (Table
S1). We estimate that lean adipose tissue contains 7.3 3 104
iNKT cells, and in obesity the numbers were reduced to 2.2 3
104 iNKT cells per two epididymal fat pads. This compares
with 7.3 3 104 iNKT in liver from lean mice and 3 3 104 iNKT in
liver from obese mice. We observed no changes in activation
markers CD69 and CD25 on iNKT cells in obesity (data not
shown). We also looked at fluctuations in other T cells in obese
fat. CD8+ T cells increased in obese fat, there were no significant
obesity-induced changes in other T cells in liver, and there was
a decrease in CD4+ T cells and an increase in CD8+ T cells in
the spleens of obese mice (Figure S1D).
HFD was replaced by a standard fat diet (SFD) for a week after
6 weeks or 10 weeks, which caused only a slight drop in total
weight but a dramatic reduction in fat-pad weight (Figure 1H).
After to the switch toSFDafter 6weeksofHFD, therewasa signif-
icant increase in iNKT cells in fat and liver; iNKT levels also began
to increase after the switch to SFD after 10 weeks of HFD (Fig-
ure 1H). These findings indicate that murine and human iNKT
cell responses to obesity and weight loss are similar.munity 37, 574–587, September 21, 2012 ª2012 Elsevier Inc. 575
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Figure 1. iNKT Cells Are Depleted in Obesity, but Are Restored Following Weight Loss in Mice and Humans
(A) iNKT cells (expressed as a%of T cells) in peripheral blood of obese patients before bariatric surgery (pre-op) (BMI > 50, n = 26) compared to lean age-matched
controls (BMI = 20-25, n = 22) and unmatched patients 18 months after surgery (post-op) (n = 18, p = 0.0002; Mann-Whitney test). Seven patients were analyzed
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iNKT Cells in Fat Protect against ObesityContribution of iNKT Cells to the Development
of Obesity
We next explored the hypothesis that iNKT cells may protect
against obesity and relatedmetabolic consequences. Ja18-defi-
cient mice lacking iNKT cells but having an otherwise normal
immune system were fed a HFD alongside age-matched wild-
type (WT) mice on HFD or SFD. Ja18-deficient mice were signif-
icantly larger before HFD challenge. They also gained signifi-
cantly more weight than WT mice on HFD, and had significantly
larger fat pads, whereas lean mass was unchanged (Figure 2A)
Food intake was similar between Ja18-deficient and WT mice
(Figure 2B). Adipocytes were larger in Ja18-deficient mice
compared toWTmice onHFD (Figures 2C and 2D). Furthermore,
Ja18-deficient mice on HFD had higher fat deposition in the liver
(Figure 2E), an elevated fasting blood glucose, an impaired
glucose tolerance test (GTT), and increased insulin resistance
compared to WT mice on HFD (Figure 2F). Serum leptin concen-
trations were equivalent in WT and Ja18-deficient mice on HFD
compared to SFD (Figure 2G).
We examined DIO in another mouse model lacking iNKT cells,
Cd1d1/mice, which lack the restriction element for iNKT cells
and therefore also selectively lack iNKT cells. Cd1d1/ mice
gained significantly more weight than WT mice on a HFD (Fig-
ure S2A). Cd1d1/ mice on HFD had higher fasting blood
glucose and worse glucose handling than WT on HFD. Fasting
insulin and insulin resistance were not significantly higher,
possibly due to higher variability inherent in these insulin assays
(Figures S2B and S2C). Cd1d1/ mice also had larger adipo-
cytes, as measured by immunohistochemistry (Figure S2D).
The above experiments were all performed on males. As
gender differences have been reported in some of the metabolic
complications of obesity (Fox et al., 2007; Medrikova et al.,
2012), we also investigated metabolic outcome in female Ja18-
deficient versus female WTmice on HFD (Figure S3). Like males,
female Ja18-deficient mice gained significantly more weight in
the first 4 weeks of HFD challenge; thereafter, weight gain was
increased but not significantly different compared to WT mice
(Figure S3A). This correlated with eating behavior; at 4 weeks,
female Ja18-deficientmice had a reduced food intake compared
to WT females, unlike males, which had almost identical food
intake patterns in WT and Ja18-deficient mice (Figure S3B).
Lean mass was similar, but both overall fat mass and fat-pad
weight were significantly higher in Ja18-deficient females (Fig-both pre- and postbariatric surgery. Middle panel, BMI of patients before and 18
(n = 7, paired t test).
(B) Left panel, iNKT (aGC-loaded tetramer+) as % of T cells (top row) and unload
matched spleen, liver, and fat. Right panel, iNKT cells (expressed as a% of T cell
(C) Left panel, representative flow cytometric plots showing the percentage o
(representative of n = 4). Right panel, concentrations of intracellular cytokines pr
(D) iNKT cytokine production after in vitro stimulation with aGC-loaded CD1d
duplicate).
(E) Representative dot plots of iNKT cell (aGC-loaded tetramer+) numbers in m
(representative of 11 experiments).
(F) iNKT cells in fat, liver, and spleen from mice on HFD for 8 weeks (n = 11) or o
(G) iNKT cell numbers measured each week on HFD in matched fat, liver, and sp
(H) Mice were removed from HFD after 6 weeks (n = 4) and after 10 weeks (n = 4).
and after removal fromHFD (orange bars) after 6 weeks (p = 0.0007) or 10weeks (p
show mean ± SD (n = 4).
*p < 0.05, **p < 0.01, ***p < 0.0001.
Imure S3A). Adipocytes were significantly larger and fewer in
number (Figure S3C), and the degree of fatty liver was greater
in Ja18-deficient females compared to WT on HFD (Figure S3D).
However, in contrast to males, fasting glucose was unchanged
and GTT was not impaired in Ja18-deficient females compared
to WT females on HFD (Figure S3E). Our findings agree with
other obesity studies (Fox et al., 2007; Medrikova et al., 2012)
that illustrate that female mice have larger fat pads and adipo-
cytes but are less susceptible to HFD-induced glucose impair-
ment and insulin resistance than male mice.
iNKT Cell Numbers Correlate Inversely with
Macrophage Infiltration in Adipose Tissue
iNKT cells can recruit and regulate other immune cells (Cerun-
dolo et al., 2009). We investigated the influence of adipose-
derived iNKT cells on macrophage infiltration and activation.
As expected, proinflammatory macrophages (F4/80+CD11c+)
increased in adipose tissue during the development of obesity,
with significant increases detectable as early as 1 week into
HFD. After cessation of HFD for 1 week, proinflammatory macro-
phages were significantly decreased in fat (Figure 3A). We found
a strong inverse correlation between iNKT cell levels in fat and
proinflammatory macrophages (Figure 3A).
To determine whether iNKT cells play a causal role in the infil-
tration and phenotype of macrophages, we investigated macro-
phage numbers in Ja18-deficient mice in obesity. In the absence
of iNKT cells, total macrophage numbers were higher in adipose
tissue (Figures 3B–3D). Adipose tissue macrophages displayed
a trend toward increased proinflammatory (CD11c) and
decreased anti-inflammatory (CD206) phenotypes in Ja18-defi-
cient mice compared to WT mice on HFD (Figure 3B). Cd1d1/
mice had similarly high numbers of F4/80 macrophages in
adipose tissue compared to WT mice on HFD (Figure S2E) but
had significantly more proinflammatory macrophages than WT
mice on HFD (Figure S2F).
Mice Lacking iNKT Cells Show Metabolic Disorder
on SFD
Both Ja18-deficient and Cd1d1/ mice have overtly normal
immune systems with no pathological susceptibilities, unless
challenged with certain pathogens or tumors. We investigated
whether there was any evidence of metabolic syndrome in
Ja18-deficient andCd1d1/mice fed ad libitum for 4–5 monthsmonths after operation. Right panel, Peripheral iNKT cell levels in each patient
ed CD1d tetramer negative control (bottom row) in a representative sample of
s) in each individual WT spleen, liver, and fat from 6–10-week-old mice (n = 24).
f iNKT cells producing each cytokine intracellularly following aGC injection
oduction by iNKT cells; mean ± SD (n = 4).
-transfected C1R cells (three independent experiments were performed in
atched fat, liver, and spleen from 10–14-week-old mice on an SFD or HFD
b/ob mice (n = 3) compared to age-matched mice on SFD (n = 11).
leen (n = 4 per week). See also Figure S2.
Graphs show overall weight (total) and fat-pad weight during HFD (green bars)
= 0.001). iNKT numbers in fat, liver, and spleen after removal fromHFD.Graphs
munity 37, 574–587, September 21, 2012 ª2012 Elsevier Inc. 577
AD E
F
C
G
B
Figure 2. Impact of iNKT Cell Deficiency on Weight Gain, Glucose Tolerance, Adipocyte Size and Number, and Fat Accumulation in Liver
(A) Weight of Ja18/ andWTmice on commencement of and during 8 weeks of HFD compared toWT on SFD (n = 4 per group per week). Overall weight gain afer
8 weeks of HFD. Lean mass and epididymal fat-pad weight of WT and Ja18/ mice on HFD; WT mice on SFD are shown for comparison.
(B) HFD food intake of WT and Ja18-deficient mice.
(C) Adipocyte diameter was measured on osmium-fixed adipocytes with a particle counter. Adipocyte size from Ja18/ andWTmice on HFD (four samples per
mouse, four mice per group).
(D) Histology of adipocytes from epididymal fat. Adipocyte size fromWTmice on SFD,WTmice on HFD, and Ja18/mice on HFD. ob/obmice are also shown for
comparison. Scale bars represent 100 mm.
(E) Histology of fat infiltration in liver of WT and Ja18/ mice on HFD (Representative of four individual experiments).
(F) Fasting glucose (left), glucose tolerance (middle), and insulin resistance (right) in WT mice on SFD, WT mice on HFD, and Ja18-deficient mice on HFD for
6 weeks (n = 4 per group, t tests, and two-way ANOVA with Tukey for GTTs). Insulin resistance, as measured by HOMA-IR (t test).
(G) Serum leptin levels in WT and Ja18-deficient mice on HFD compared to WT mice on SFD (n = 4 per group, ANOVA). Graphs show mean ± SD.
*p < 0.05, **p < 0.01, ***p < 0.0001.
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iNKT Cells in Fat Protect against Obesityon SFD. Both Ja18-deficient mice and Cd1d1/ mice consis-
tently weighed more (Figure 4A) and had larger adipocytes on
SFD compared to aged-matched WT mice (Figure 4B). Adipose
tissue macrophages were markedly increased in both types of
iNKT cell-deficient mice, but had similar proinflammatory (data
not shown) and anti-inflammatory phenotypes in each group
on SFD (Figure 4C). Consistent with these findings, both Ja18-
deficient and Cd1d1/ mice had greatly increased serum
triglyceride numbers and TNF-a concentrations as well as some-
what elevated IL-6 concentrations (Figure 4D). Ja18-deficient
mice and Cd1d1/ mice on SFD had elevated fasting glucose,
and GTT was slightly impaired inCd1d1/mice, although these
differences were not significant (Figure 4E).
Transfer of iNKT Cells in Obese Ja18-Deficient Mice
Improves Glucose Handling
To directly test the hypothesis that iNKT cells play a protective
role against the development of obesity-induced metabolic
syndrome, we adoptively transferred 5 3 105 WT hepatic iNKT578 Immunity 37, 574–587, September 21, 2012 ª2012 Elsevier Inc.cells into obese mice (>8 weeks on HFD), who were continued
on HFD for 4 days. Adoptive transfer of 5 3 105 NKT cell-
depleted T cells or PBS were used as controls. Adoptive transfer
of iNKT cells resulted in significant weight loss and a dramatic
reduction in adipocyte size, compared to transfer of T cells or
PBS (Figures 5A and 5B). Mice that received NKT cells had
similar numbers of macrophages as mice that received T cells
but had less proinflammatory marker CD11c expression (Fig-
ure S4). Food intake was similar between mice receiving iNKT
cell transfer or PBS alone (data not shown). Mice that received
iNKT cells had significantly smaller fat pads than PBS controls,
whereas fat-pad size in the T cell recipients was intermediate
between PBS and iNKT cells (Figure 5C). Importantly, lean
control mice that received the same number of iNKT cells did
not lose weight (Figure 5D) or have hypoglycemia (Figure 5E)
compared to PBS alone. Obese mice that received iNKT cells
had significantly lower fasting glucose (Figure 5F) and improved
GTT (Figure 5G) compared tomice receiving PBS, whereas T cell
recipients were again intermediate between PBS and iNKT cell
AB
C
D
Figure 3. The Relationship between Adipose iNKT Cells and Macrophages
(A) Left panel, proinflammatory macrophage (Proinflammacs; F4/80+CD11c+MMR+) levels in fat (as% SVF) of WTmice fed HFD (red) or SFD (blue) for 10 weeks.
Dashed line shows when HFD was replaced with SFD (black). Right panel, correlation between iNKT cell levels and macrophage numbers in fat; Pearson r =
0.9612, p = 0.0001.
(B) Left panel, representative dot plots of % F4/80+ total macrophages per fat pad (top), the%macrophages that are CD11c+ (proinflammatory) (middle), and the
% macrophages that are CD206+ (anti-inflammatory) (bottom) in WT mice on SFD, WT mice on HFD, and Ja18-deficient mice on HFD. Right panel, levels and
phenotypes of macrophages from individual mice groups (n = 4 mice per group), including number of CD68+ macrophages as measured by immunohisto-
chemistry (n = 20 low power fields per group).
(C) Immunohistochemical staining of F4/80+ macrophages in fat from WT mice on SFD, WT mice on HFD, Ja18/ mice on HFD, and ob/ob mice on SFD
(representative of four mice per group).
(D) Immunohistochemical staining of CD68+ M1 macrophages in fat from WT on SFD and WT and Ja18-deficient mice on HFD (representative of four mice per
group). Scale bars represent 100 mm.
*p < 0.05, **p < 0.01, ***p < 0.0001
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iNKT Cells in Fat Protect against Obesityrecipients. Insulin sensitivity improved after iNKT cell transfer,
but not T cell transfer (Figure 5H). Next, we cultured fat pads
overnight from mice that received NKT cells or PBS in vivo and
performed an array analysis on the supernatant from the cultured
fat pads. Mice that received NKT cells had similar amounts of the
adipokine resistin but had significantly less leptin and signifi-
cantly more adiponectin. Furthermore, angiopoietin-like 3
(ANGPTL3) production was greatly reduced, and IL-10 produc-
tion was increased, probably produced by iNKT cells (Figure 5I).
aGC Treatment Causes Weight Loss and Adipocyte
Hypertrophy and Improves Fatty Metabolic Disorder
We investigated whether aGC, the prototypical ligand for iNKT
cells, could activate residual iNKT cells in obesity and subse-
quently improve metabolic outcome. Following one injection ofImaGC into WT obese mice (>8 weeks on HFD) and continued
HFD for 4 days, mice lost a significant amount of weight; their
percentage body fat also decreased significantly, although
lean mass did not change (Figures 6A and 6B). aGC also caused
a rapid reduction in adipocyte size (Figure 6C). Food intake was
similar between treatment and control. aGC caused a marked
reduction in fasting blood glucose compared to vehicle control
(Figure 6D). Obese Ja18-deficient mice lacking iNKT cells did
not loseweight after aGC treatment (Figure 6A) or have improved
glucose concentrations, which were extremely high (Figure 6D).
aGC returned GTT to almost normal inWTmice on HFD, unlike in
obese Ja18-deficient mice. aGC treatment did not significantly
affect fasting glucose or GTT in normal-weight mice on SFD (Fig-
ure 6D). aGC significantly improved insulin resistance as
measured by homeostatic model of assessment insulinmunity 37, 574–587, September 21, 2012 ª2012 Elsevier Inc. 579
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Figure 4. iNKT Null Mice Have More Proinflammatory Cytokines and Macrophages on an SFD
(A) Weight of WT, Ja18/, and CD1d1/ mice fed SFD ad libitum until 20 weeks of age (n = 3 per group, one-way ANOVA with post hoc Tukey).
(B) Adipocyte size in WT, Ja18-deficient, and CD1d1/ mice on SFD (representative of three mice per group).
(C) Macrophage level and phenotype in the three mice groups on SFD. Left top, total macrophages; left bottom, M2 (CD206+) macrophages; CD206 hi (top gate),
CD206lo (middle gate), and CD206 (bottom gate). SSC, side scatter.
(D) Fasting serum triglyceride (TGL) concentration in the three groups (n = 3, all one-way ANOVAwith post hoc Tukey). Serum TNF-a and IL-6 concentration inWT
and Ja18/ mice on SFD (n = 3, t test); CD1d1/ mice not tested.
(E) Fasting glucose and glucose tolerance of 20 week old WT, Ja18/, and CD1d1/ mice on SFD.
Graphs show mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.0001.
Immunity
iNKT Cells in Fat Protect against Obesityresistance (HOMA-IR), although the insulin tolerance test (ITT)
was not significantly different due to variability in baseline fasting
insulin (Figure 6E). aGC lowered serum triglyceride numbers,
circulating leptin, and IL-6 in obeseWTmice (Figure 6F). Surpris-
ingly, TNF-a concentrations were increased (Figure 6F). IL-4 was
not significantly increased after aGC, and serum IL-10 was
below the detection range (data not shown). aGC treatment
improved fatty liver; fat droplets were smaller and less frequent,
compared to mice that received vehicle (Figure 6G).
We examined iNKT cells 4 days post-treatment with aGC, at
the time of metabolic analysis. aGC caused dramatic expansion
in numbers of iNKT cells in fat, as well as a smaller but significant
expansion in spleen and liver (Figure 7A). aGC activated iNKT
cells to produce anti-inflammatory cytokines (Figure 7A), prob-
ably leading to the improvement in metabolism despite HFD580 Immunity 37, 574–587, September 21, 2012 ª2012 Elsevier Inc.feeding (Figures 6A–6E), although iNKT cells also produced
some IFN-g following aGC. Furthermore, iNKT cells in adipose
tissue were still producing cytokines 4 days postinjection, unlike
those in spleen and liver (Figure 7A). We next investigated
whether aGC could mediate metabolic protection if IL-4 and
IL-10 were neutralized before aGC injection. When both IL-4
and IL-10 were neutralized immediately prior to aGC treatment,
mice still lost weight (Figure 7B); however, fasting glucose
concentrations were elevated compared to aGC treatment alone
(Figure 7C). Furthermore, neutralizing these cytokines resulted in
increased glucose concentrations during the GTT at 60 and
90 min, like vehicle control, and unlike aGC alone, which signif-
icantly improved GTT at each time point. Blocking these cyto-
kines resulted in increased insulin resistance at 15 and 30 min
time points compared to aGC treatment alone (Figure 6E). We
Figure 5. Adoptive Transfer of iNKT Cells Protects from Weight Gain and Adipocyte Hypertrophy and Reverses Obesity-Associated Meta-
bolic Disorders
WT iNKT cells (>95% pure), iNKT cell-depleted T cells (T), or no-treatment (PBS) control were injected i.p. into 18–20-week-old DIO mice on HFD for 12 weeks;
they continued on HFD for 4 days.
(A) Difference in weight pre- and 4 days postadoptive transfer of mice that received iNKT cells (n = 10), PBS (n = 6), or T cells (n = 6).
(B) Adipocyte diameter of obese mice that received iNKT cells versus T cells or PBS control (two samples per mouse; n = 4 for PBS and NKT, n = 3 for T cells;
ANOVA with Tukey).
(C) Epididymal fat weight after iNKT transfer (n = 10) compared to PBS (n = 6) or T cell transfer (n = 6), with WT mice on SFD for comparison (n = 4).
(D and E) Weight change (D) and fasting glucose (E) in lean WT mice that received NKT cell transfer.
(F and G) Fasting glucose (ANOVA) (F) and glucose tolerance (G) following iNKT transfer (n = 8) compared to PBS (n = 4) or T cell transfer (n = 4), with WT mice on
SFD for comparison (n = 4, two-way ANOVA).
(H) ITT in obese mice was measured 4 days post transfer of iNKT cells (n = 4), PBS (n = 4), T cells, or WT on SFD (n = 3) (two-way ANOVA with Tukey post hoc).
(I) Following adoptive transfer of iNKT cells for 3 days, adipose tissue was harvested and cultured. Production of resistin, leptin, adiponectin, ANGPTL3, and IL-10
were measured by protein array (n = 2 of two pooled mice each).
Graphs show mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.0001.
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alone prior to aGC partly prevented the improvement in fasting
glucose seen with aGC (Figures S6A and S6C). It is possible
that blocking IL-4 or IL-10 without aGC could also be beneficial
through another pathway, such as macrophages; however,
neutralizing antibody treatment alone without aGC did not
improve or worsen GTT compared with PBS (Figure S5D).ImDISCUSSION
We have identified a role for iNKT cells in the regulation of body
weight and metabolic state. Our results indicate that iNKT cells
may act through regulation of inflammation in adipose tissue,
although whether this effect is direct or indirect is not fully clear.
Previous data from human and murine studies suggest thatmunity 37, 574–587, September 21, 2012 ª2012 Elsevier Inc. 581
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Figure 6. aGC Treatment Reverses Obesity-Associated Metabolic Disorders
(A and B) Effect of aGC treatment on weight gain and adipocytes.
(A) Difference in weights before and 4 days after aGC or vehicle (VEH) treatment (n = 7 per group, t test).
(B) Lean mass and % body fat measured by DEXA following aGC treatment (n = 5, t test).
(C) Adipocyte size following aGC treatment (two samples per mouse, n = 4 mice, t test).
(D) Oil red O staining in liver samples fromWT obesemice 4 days post aGC injection. Two representative images per treatment (representing fivemice per group).
(E) Fasting glucose and GTT of WT obese mice 4 days post aGC injection (n = 5, fasting glucose: t test; GTT: two-way ANOVA with post hoc shown; area under
curve ***p = 0.0007).
(F) GTT following aGC treatment into lean WT mice on SFD (n = 4 per group).
(G and H) Insulin resistance as measured by HOMA-IR (G) and ITT (H) following aGC treatment (n = 4).
(I) Circulating triglyceride (TGL), leptin, IL-6, TNF-a, and IL-4 following aGC treatment (n = 5 each, all t tests).
Graphs show mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.0001.
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iNKT Cells in Fat Protect against Obesityadiposity due to diet (and negative energy expenditure) is the
trigger for increased adipose tissue inflammation, which subse-
quently leads to insulin resistance and metabolic disorder. In
obesity, excess lipid leads to larger, stressed adipocytes that
produce proinflammatory adipokines and cytokines, leading
to downstream negative effects on insulin sensitivity. Influ-
encing the function of adipocytes has potentially significant
health benefits. We and others have shown that increasing
adipocyte size correlates with insulin resistance, triglyceride
levels, and the degree of hepatic steatosis (Lo¨nn et al., 2010;
O’Connell et al., 2010). One hypothesis is that adipocytes are
dysfunctional when filled to capacity (3 mg lipid per cell) (Dan-
forth, 2000), causing ‘‘overflow’’ of lipids to muscle and liver
(Gregor and Hotamisligil, 2007) and leading to overproduction
of glucose and high fatty-acid levels, which can activate the
kinases JNK and IKK, leading to insulin resistance at these582 Immunity 37, 574–587, September 21, 2012 ª2012 Elsevier Inc.sites (reviewed by Guilherme et al., 2008; Hotamisligil and
Erbay, 2008). iNKT cell-deficient mice had larger adipocytes,
even on SFD, and when iNKT cells were reintroduced or acti-
vated, adipocytes rapidly reduced in size. Importantly, iNKT
cell transfer did not cause weight loss or hypoglycemia in
lean control mice. Furthermore, mice that received iNKT cells
had significantly higher levels of adipose tissue adiponectin,
an insulin-sensitizing adipokine produced largely by adipo-
cytes. Moreover, fat from iNKT cell transfers had significantly
less leptin and ANGPTL2 production, which are key mediators
of chronic adipose tissue inflammation and insulin resistance.
The production of anti-inflammatory cytokines by iNKT cells
may have direct affects on adipocytes. IL-10, which was
increased in adipose tissue following iNKT cell transfer, can
protect adipocytes from the physiological insulin-desensitizing
effects of TNF-a seen in obesity (Hong et al., 2009; Lumeng
AB C
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Figure 7. aGCTreatment Expands Adipose iNKTCells and Activates Their IL-4 and IL-10 Production, Resulting in ImprovedMetabolic Health
(A) Left panel, iNKT cell levels in adipose tissue, liver, and spleen at 4 days post aGC injection. Right panel, IFN-g, IL-4, and IL-10 production by iNKT cells from
each organ postactivation. Quadrant percentages represent cytokine production by iNKT cells after subtraction of control (control for fat shown on bottom row).
(B) Obese mice received neutralizing IL-4 and IL-10 (n = 7) antibodies before aGC treatment. Weight loss post treatment with or without neutralizing antibodies is
shown.
(C) GTT and insulin resistance test in obese mice where IL-10 and IL-4 were neutralized prior to aGC (n = 7, two-way ANOVA and t test).
*p < 0.05, **p < 0.01, ***p < 0.0001.
Immunity
iNKT Cells in Fat Protect against Obesityet al., 2007) and probably leads to ‘‘healthier’’ adipocytes, re-
flected in lower levels of circulating proinflammatory cytokines
and leptin.
iNKT cells may also indirectly affect adipocytes through their
effects on macrophage function. The production of IL-10 was
unique to iNKT cells in adipose tissue, and IL-10 and IL-4 are
potent inhibitors of proinflammatory cytokines (Williams et al.,
2004). IL-10 promotes a phenotypic switch in macrophage acti-
vation toward an anti-inflammatory phenotype (Williams et al.,
2004). Adipocyte hypertrophy can lead to cell death, triggering
an inflammatory response from macrophages, which form
crown-like structures surrounding dead adipocytes. This causes
a phenotypic switch in macrophages from M2 to M1, which also
contributes to adipose tissue inflammation (Dalmas et al., 2011).
iNKT numbers were strongly inversely correlated with proinflam-
matory macrophage numbers in fat, and reintroduction or acti-
vation of iNKT cells caused a marked decrease in adipose
tissue-associated macrophages. These findings and another
recent study (Winer et al., 2009) show that adoptive transfer of
conventional T cells offered some relief in the metabolicImsyndrome, compared to PBS, although the effect was not as
potent as in iNKT cell transfer. The partially protective effect of
T cell transfer into obese mice is not surprising given that
CD4+ T cell transfer into obese mice reversed weight gain and
insulin resistance (Winer et al., 2009), an improvement that
was found to be due to both FoxP3 positive and negative CD4
T cells. Another recent study found that Treg cells alone did
not significantly restore all metabolic function in obesity (Feuerer
et al., 2009), although this could be due to difficulties in
complete gain or loss experiments involving Treg cells. Our
conventional T cell transfer also included Treg cells, which likely
contributed to the benefits in metabolism. Conversely, it is
possible that iNKT cells were likely a contaminant in previous
studies that used adoptive transfer of CD4+ T cells in obesity,
given that iNKT cells are a subpopulation of CD4+ T cells in
fat, liver, and spleen. From these combined data, we could
draw the conclusion that iNKT cells are sufficient and possibly
more effective at improving glucose handling, but are not the
only immune cell type in adipose tissue that is involved in meta-
bolic regulation.munity 37, 574–587, September 21, 2012 ª2012 Elsevier Inc. 583
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iNKT Cells in Fat Protect against ObesityOur results from two iNKT cell-deficient models show that
mice lacking iNKT cells are more affected by HFD and, even
on an SFD, gained more weight with age than controls did. In
this study, we did not use littermate controls in our iNKT-defi-
cient models, due to lack of availability. Therefore, there is
a possibility that weight gain or metabolic changes seen could
be wholly or partly due to different weaning or early changes,
which have been shown to be very important in metabolism
during the life of animals. In this case, we believe this is unlikely,
because iNKT cells are thought to arise postnatally at day 5 in the
thymus and at 1–2 weeks in the periphery (Pellicci et al., 2002).
We found that WT and mutant mice had similarly sized litters
with similar birth weights; additionally, it was only with age
(>4 months) that differences were seen on an SFD. Our results
also suggest that the severe obesity in leptin deficient ob/ob
mice causes iNKT cell depletion. The presence of leptin itself
does not appear to be essential for iNKT cell survival, as leptin
levels are elevated in obesity, whereas iNKT cells are depleted.
Previous studies show that ob/ob mice have aberrant hemato-
poiesis and immune defects (Fantuzzi and Faggioni, 2000; Macia
et al., 2006), including decreased iNKT cells in livers from ob/ob
mice (Yang et al., 2007). Given that iNKT cells are thought to be
absent at birth (Kronenberg and Gapin, 2002; Pellicci et al.,
2002), and ob/ob mice are already significantly larger than their
WT littermates very soon after birth, effects of excess adiposity
cannot be ruled out.
The role of iNKT cells in regulation of metabolism is just
emerging, although it has previously been described that iNKT
cells are reduced in livers of obese mice (Ma et al., 2008; Yang
et al., 2007), leading to hepatic insulin resistance, and that
increasing iNKT cells in obese liver improved hepatic steatosis
and glucose tolerance (Ma et al., 2008; Elinav et al., 2006). During
the review of our manuscript, Ji et al. (2012) also reported that
iNKT cells are decreased in human and murine obesity, confirm-
ing our previous (Lynch et al., 2009) and current findings.
Furthermore, both our groups found that activation of iNKT cells
with aGC led to macrophage polarization to an M2 phenotype
and improved glucose sensitivity through anti-inflammatory
cytokine signaling (Ji et al., 2012). Similarly, Kotas et al. (2011)
found that iNKT cells were selectively depleted in obese livers
and that Cd1d1/ mice had slight but significantly increased
steatosis and impaired hepatic glucose tolerance. Their findings,
however, were not as dramatic as our results in obese iNKT-defi-
cient mice. Furthermore, the protective role of iNKT cells was
further questioned when Ohmura et al. (2010) reported that
mice lacking iNKT cells were protected against obesity.
However, this study used b2-microglobulin-deficient mice,
which lack both CD8+ T cells and iNKT cells, and CD8 T cells
are reported to be pathogenic in obesity (Nishimura et al.,
2009). To address this, Mantell et al. (2011) used CD1d/
mice, and in contrast to our and others’ studies, found no differ-
ence between CD1d/ and WT mice on a HFD, although the
conclusion was drawn that the deletion of NKT cells was insuffi-
cient to protect against the development of the metabolic abnor-
malities of obesity. Another study (Satoh et al., 2012) described
that CD1d/ mice gained less weight than WT mice with less
steatohepatitis, implying that NKT cells are pathogenic in
obesity, in contrast to previously published studies (Elinav
et al., 2006; Ji et al., 2012; Kotas et al., 2011; Ma et al., 2008;584 Immunity 37, 574–587, September 21, 2012 ª2012 Elsevier Inc.Yang et al., 2007). These discrepancies between iNKT-deficient
studies are difficult to resolve, although there are some key
differences in experimental approach between studies. Most
importantly, Mantell et al. (2011) used NK1.1+ T cells as a marker
of iNKT cells, although not all invariant NKT cells express NK1.1,
and in fat, iNKT cells express less NK1.1 than elsewhere; lastly,
not all NK1.1+ T cells are CD1d-restricted. However, this study
found that iNKT cells were depleted in obesity, similar to ours
and others that describe a loss of iNKT cells in obesity that leads
to a worsening metabolic outcome. The discrepancies in results
with iNKT-deficient mice between different laboratories may not
yet be explained, but the adoptive transfer of iNKT cells into
obese mice and the specific activation of iNKT cells with aGC
provide amore conclusive demonstration of the positive benefits
of iNKT cells against obesity-related disorders. Furthermore, our
murine data parallel our human results on the effects of weight
gain and loss on iNKT cells.
In humans, iNKT cell levels correlate negatively with weight
gain (Lynch et al., 2009). Following the return to SFD in mice or
weight loss in humans, iNKT levels are increased, demonstrating
the reversibility of iNKT cell defects. Likewise, despite severe
numerical defects, the reduced iNKT cell pool in murine obesity
is still capable of marked expansion and production of anti-
inflammatory cytokines, leading to dramatically positive effects
on adipocytes and metabolism. Whether treatments that
increase or activate iNKT cells will have beneficial effects in hu-
mans with metabolic syndrome remains to be determined. The
use of aGC to activate iNKT cells in humans has been employed
in multiple cancer settings. It has proven to be safe, with no
reports of hepatotoxicity, unlike inmice, wherein repeated higher
doses in older animals can cause hepatotoxicity (Exley et al.,
2011). The observation that targeting the iNKT cell system with
aGC inmice did not cause hypoglycemia in the diabetic or eugly-
cemic model suggests a restoration of physiological balance.
This is potentially very attractive from a therapeutic perspective.
Immuno-metabolic interaction in obesity is now established as
a key factor in adipose tissue inflammation and subsequent
development of type 2 diabetes. It also holds exciting possibili-
ties for the development of a new treatment paradigm for this
disorder, which is currently at epidemic proportions. Our study
supports the emerging view that T cells and macrophages play
important roles in adipose tissue function and identifies iNKT
cells as amajor regulatory T cell population in fat. Further studies
exploring the therapeutic potential of iNKT cells in obesity and
metabolic syndrome are warranted.
EXPERIMENTAL PROCEDURES
Mice
Male (and where indicated, female) WT C57BL/6 and ob/ob mice were
purchased from Jackson Laboratories (Bar Harbor, ME, USA). Ja18-deficient
mice and C57BL/6J CD1d1/mice have been described (Exley et al., 2003).
Ja18-deficient (F9) and CD1d1/ (F12) mice were backcrossed on the
C57BL/6 background. Mice were housed adjacently from birth and fed
the same chow (SFD or HFD). In general, experiments began with 6-week-
old male mice. For metabolic studies, the mice received either SFD or
HFD (Research Diets, 60 kcal% fat for the HFD) from 6 weeks of age, for
6 weeks, or 12 weeks where indicated. Mice were housed under specific
pathogen-free conditions. Animal experiments were performed in accor-
dance with protocols approved by the Institutional Animal Care and Use
Committee.
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Ten milliliters of peripheral blood were obtained from 26 consecutive obese
subjects who were referred to our hospital-based weight-management clinic
(mean age 47, range 24–60 years; mean BMI 48), 18 patients attending the
weight management clinic 18 months after bariatric surgery (mean age 46,
range 36–54 years; mean BMI 38), and 22 lean healthy controls (mean age
39, range 23–54 years; mean BMI 24). All blood samples were obtained with
written informed consent. The ethics committee at St. Vincent’s University
Hospital, Dublin granted approval for this study.
Reagents
aGC analog PBS-57-loaded or empty CD1d tetramers were provided by the
National Institutes of Health (NIH) tetramer facility (Emory Vaccine Center, At-
lanta). aGC (KRN 7000) was kindly provided by Kirin, Japan. Immune cells
were cultured in RPMI-1640 and adipose tissue-derived cells in Dulbecco’s
modified Eagle’s media (DMEM) supplemented with penicillin, streptomycin
(Mediatech, Manassas, VA, USA), and 5% fetal bovine serum (HyClone,
Logan, UT, USA).
Diet and Metabolic Studies
WT, Ja18-deficient, and CD1d1/ mice were weighed weekly, and food
intake was monitored on HFD. Body fat content was measured by a dual-
energy X-ray absorptiometry (DEXA) scan performed after mice were sacri-
ficed. Whole abdominal adipose fat pads were weighed after dissecting out
the testes and lymph nodes. After 6 weeks on HFD, fasting blood glucose
(OneTouch Ultra) and insulin concentrations (Crystal Chem ELISA) were
measured. For glucose tolerance tests, fasted (10 hr) mice received 1 g
glucose per kg body weight intraperitoneally (i.p.), and glucose levels were
measured every 15min for 90min. For insulin resistance, HOMA-IR calculation
(Matthews et al., 1985) was used: fasting blood glucose 3 fasting insulin O
22.5. Two samples of 5mm liver were collected and fixed in formalin overnight,
prior to paraffin mounting and preparation of hematoxylin and eosin (H&E)- or
oil red O-stained slides for measurement of fatty liver. For H&E and oil red O
staining, biopsies were viewed using the 203 objective. The degree of fatty
liver was measured by oil red O staining intensity around five portal-tract areas
per slide.
Adipocyte Size
Adipocyte size and number were measured by osmium and immunohisto-
chemistry. Two samples of 20–30mg of adipose tissue per mouse were imme-
diately fixed in osmium tetroxide (3% solution in 0.05 M collidine), minced into
1 mm pieces and incubated in the dark at room temperature for 48 hr. Adipose
cell size and number were determined by a Beckman Coulter Multisizer 3 with
a 400 mm aperture. Adipose tissue was also fixed in formalin overnight, prior to
paraffin mounting and preparation of H&E slides. The adipocyte number was
counted per field of view, in ten fields per sample, and related back to the orig-
inal weight of each fat pad.
Spleen, Liver, and Adipose Tissue and Human Blood Preparations
Isoflurane-anesthetizedmicewere systemically perfusedwith PBS. Single-cell
suspensions from spleens were prepared by standard techniques. Liver
mononuclear cells (LMNCs) were isolated as previously described without
collagenase digestion (Nowak et al., 2010). In brief, livers were perfused with
PBS and minced, and iNKT cells were enriched by centrifugation in a two-
step Percoll gradient. Enriched populations typically contained 20%–30%
iNKT cells. Epididymal adipose tissue was dissected, carefully avoiding lymph
nodes, mincedwith opposing scalpels, and digested with collagenase (Sigma-
Aldrich, 0.2 mg/ml1 in DMEM for 45 min at 37C on a rotary shaker). The
digests were filtered through 40 mm cell strainers and pelleted to enrich fat-
associated lymphocytes in the stromovascular fraction (SVF). Cell yields and
viability were measured with trypan blue staining. Ten milliliters of venous
blood was collected in heparinized tubes for measurement of iNKT cell levels.
Peripheral blood mononuclear cells were prepared by standard density
gradient centrifugation over Lymphoprep (Nycomed) at 400 g for 25 min. Cells
were thenwashed twicewith Hank’s balanced salt solution supplementedwith
HEPES buffer solution (Invitrogen Life Technologies) and antibiotics. Cell
pellets were resuspended in 1 ml of RPMI-1640 medium, and cell yields and
viability were assessed by ethidium bromide and acridine orange staining.ImThe cell suspension was adjusted to 1 3 106 cells/ml in RPMI for staining
(100 ml/tube).
Flow Cytometry
Single-cell suspensions of splenocytes, LMNCs, and adipose SVF were
blocked with CD16/32 monoclonal antibody (mAb) and stained for 30 min at
4C in the dark with PBS-57-loaded or empty CD1d tetramer-PE (NIH tetramer
facility) and CD3 (1:150 dilution, eBioscience). Macrophages were labeled with
phycoerythrin (PE)-conjugated antibody to F4/80 (1 in 100), CD11c (1in 200),
and CD206 (1 in 200) to differentiate M1 from M2 macrophages in the SVF,
as previously described (Fujisaka et al., 2009). For human peripheral blood,
mouse anti-human CD3 combined with the iNKT TCR (6B11) and isotype-
matched controls were used (BD Biosciences). iNKT cells were also stained
with Va24 and Vb11 TCR chains from Coulter Immunotech (Marseilles,
France). Cells were washed and fixed in 1% paraformaldehyde and acquired
on an LSR II flow cytometer (BD Biosciences) and with FlowJo and Kaluza
software.
iNKT Cell Isolation and Adoptive Transfer
Hepatic mononuclear cells were stained with CD1d tetramer-PE and sorted to
>95% purity using a FACSAria II (Becton Dickinson, San Jose, CA, USA). Puri-
fied iNKT cells (5 3 105) were injected i.p. into Ja18-deficient mice that had
been on HFD for 8 weeks. Metabolic parameters were analyzed after
4 days, mice were sacrificed, adipose tissue was weighed, and adipocytes
were measured by osmium and immunohistochemistry.
In Vivo Stimulation of iNKT Cells and Intracellular Cytokine Staining
Mice were injected i.p. with 2 mg of aGG or vehicle alone and sacrificed after
5 hr or 4 days, at the time of metabolic analysis. Single-cell suspension of sple-
nocytes, LMNCs, and adipose tissue SVFs were obtained as before, but with
the inclusion of Brefeldin A in all media. First, single-cell suspensions of
splenocytes or LMNCs were stained with cell-surface-labeling CD3 mAb
and aGC-loaded CD1d tetramer. Cells were then fixed, permeabilized, and
stained intracellularly for IL-4, IL-10, and IFN-g using the Cytofix/Cytoperm
kit (BD Biosciences), according to the manufacturer’s instructions. To
neutralize cytokines prior to aGC treatment, anti-IL-4 (11B11) or anti-IL-10
(JES5-2A5) were injected i.p. prior to injection of aGC.
Statistical Analyses
Error bars represent SEM. The statistical significance of differences between
two groupswas determined using theMann-WhitneyU test or Student’s t tests
where appropriate following determination of Gaussian distribution of the data.
Differences among mice groups (>2) were evaluated using one-way or two-
way ANOVA followed by post hoc Tukey tests. Values of p < 0.05 were consid-
ered significant.
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